BIOMAT Database Logo BIOMAT Database Logo

Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease. 2010

K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.

OBJECTIVE To evaluate the association between cerebrospinal fluid (CSF) homovanillic acid (HVA) concentrations and nigrostriatal dopaminergic function assessed by positron emission tomography (PET) imaging with carbon-11-labeled 2beta-carbomethoxy-3beta-(4-fluorophenyl)-tropane ((11)C-CFT), which can measure the dopamine transporter (DAT) density, in Parkinson's disease (PD). METHODS (11)C-CFT PET scans and CSF examinations were performed on 21 patients with PD, and six patients with non-parkinsonian syndromes (NPS) as a control group. RESULTS In the PD group, CSF HVA concentrations were significantly correlated with the striatal uptake of (11)C-CFT (r = 0.76, P < 0.01). However, in the NPS group, two indices were within the normal range. CONCLUSIONS In PD, CSF HVA concentrations correlate with nigrostriatal dopaminergic function. Therefore, CSF HVA concentrations may be an additional surrogate marker for estimating the remaining nigrostriatal dopaminergic function in case that DAT imaging is unavailable.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005260 Female Females
D006719 Homovanillic Acid A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid. 3-Methoxy-4-Hydroxyphenylacetic Acid,4-Hydroxy-3-Methoxyphenylacetic Acid,3 Methoxy 4 Hydroxyphenylacetic Acid,4 Hydroxy 3 Methoxyphenylacetic Acid,Acid, 3-Methoxy-4-Hydroxyphenylacetic,Acid, 4-Hydroxy-3-Methoxyphenylacetic,Acid, Homovanillic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D001479 Basal Ganglia Large subcortical nuclear masses derived from the telencephalon and located in the basal regions of the cerebral hemispheres. Basal Nuclei,Ganglia, Basal,Basal Nuclear Complex,Ganglion, Basal,Basal Nuclear Complices,Nuclear Complex, Basal,Nuclei, Basal

Related Publications

K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease.
January 2007, Journal of neurology,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture.
January 1995, Neurology,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
[The neuropsychology of nigrostriatal dopaminergic transmission in Parkinson's disease].
December 2011, Fortschritte der Neurologie-Psychiatrie,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease.
February 2019, Movement disorders : official journal of the Movement Disorder Society,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Function and Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons in Motor Control and Parkinson's Disease.
January 2021, Frontiers in neural circuits,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
April 2000, Annals of neurology,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
October 1991, Neurology,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Tuberoinfundibular dopaminergic function in Parkinson's disease.
January 1988, European neurology,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease.
November 2005, European journal of neurology,
K Ishibashi, and K Kanemaru, and Y Saito, and S Murayama, and K Oda, and K Ishiwata, and H Mizusawa, and K Ishii
Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease.
June 2023, European journal of neurology,
Copied contents to your clipboard!